News and Comments

Biotechnology Companies: A Model that’s Gaining Visibility

  Tuesday, December 07, 2010

The biotechnology company model founded on management skills rather than purely on scientific skills has begun to gain investors’ appreciation. The reason is that many firms built around skilled, experienced entrepreneurs have succeeded in bringing a large number of drugs to the market and in marketing them competently. These firms license or acquire drugs in mid-or late-phase trials. They sometimes acquire therapeutic molecules in early-stage development only if these molecules prove to have optimal affinity on validated proteins in pathways of diseases, and produce desired agonist or antagonist effects. In order to select the products that can be called breakthroughs, the most successful of the firms established and run by entrepreneurs with strong business acumen employ specialists in pharmaceutical sciences and in clinical trials. These scientists have experience in sensitive areas such as drug development, clinical trials, medicinal chemistry, and other important disciplines required for drug discovery, development and testing.   More...

Recent Postings



NANTKWEST (NK) Seattle Genetics (SGEN) GlaxoSmithKline (GSK) GUARDIAN HEALTH NEUROCRINE (NBIX) Idenix (IDIX) C4 Therapeutics Ridaforolimus AstraZeneca (AZN) IDERA (IDRA) Exelixis (EXEL) Dynavax (DVAX) Sangamo (SGMO) Sanofi (SNA) Intercept (ICPT) BIOMARIN (BMRN) Genentech Benlysta (belimumab) Telaprevir Biocryst (BCRX) Theravance Bio Pharma (TBPH) Multiple Myeloma Bristol-Myers Squibb (BMY) ARGOS (ARGS) ISIS (ISIS) Inovio (INO) Cytokinetics (CYTK) Alder Biopharmaceuticals (ALDR) Bellicum (BLCM) Velcade (bortezomib) INNOVIVA (INVA) LEXICON (LXRX) Auspex (ASPX) ACADIA (ACAD) Intrexon (XON) SUNESIS PHARMACEUTICALS (SNSS) Rapamune Merck (MRK) ADVENTRIX (ANX) Adaptimmune (ADAP) OSI (OSIP) Human Genome Sciences (HGSI) Intermune (ITMN) Gilead (GILD) ABBVIE (ABBV) Spike Therapeutics (ONCE) AGOS (ARGS) Ionis (IONS) Sanofi-Aventis (SAN) Trastuzumab-DM1 Endometrial Cancer Theravance (THRX) Xoma (XOMA) Sarepta (SRPT) Alnylam (ALNY) ImmunoGen (IMGN) Vertex (VRTX) VANDA (VNDA) Biogen Idec (BIIB) ZALTRAP™ Incyte (INCY) Tysabri Ocular Therapeutix (OCUL) Editas (EDIT) Array Pharmaceuticals (ARRY) Regeneron (REGN) SERES THERAPEUTICS (MCRB) JOUNCE THERAPEUTICS (JNCE) REGULUS (RGLS) KERYX (KERX) Roche (RHHBY) Micromet (MITI) HALOZYME (HALO) MODERNA Sanofi (SNY) galapagos (GLPG) Galena (GALE) Dendreon (DNDN) Ariad (ARIA) Advaxis (ADXS) Prolor Biotech (PBTH) Aimmune Therapeutics (AIMT) AERIE PHARMACEUTICALS SYNTA (SNTA) Sequenom (SQNM) Illumina (ILMN) CEMPRA (CEMP) NOVOCURE (NVCR) CRISPR Therapeutics (CRSP) NEKTAR (NKTR)) Agenus (AGEN Ziofpharm (ZIOP) Zerenex Global Cell Therapeutics (GBT) Pluristem (PSTI) Vitae Pharmaceuticals (VTAE) Human Longevity (HLI) ARCA (ABIO) Roche (ROCHE) Agenus (AGEN) Revlimid (lenolidamide) TOKAI (TKAOI) Anacor (ANAC) JUNO (JUNO) Abbott Laboratories (ABT) CompuGen (CGEN) PORTOLA (PTLA) Jazz Pharmaceuticals (JAZZ) RenenxBio (RGNX) Herceptin Valeant Pharmaceuticals International (VRX) OncoCyte (OCX) Elan (ELN) PTC Therapeutics (PTCT) Anadys (ANDS) KITE (KITE) Amgen (AMGN) Onyx (ONXX) Prosensa (RNA) Mirati Therapeutics (MRTX)